Nothing says Christmas like a good investment book! So get the investment book lover on your list a copy of Abnormal Returns: Winning Strategies from the Frontlines of the Investment Blogosphere today.


A Q&A with Matt Egan on what comes after the risk-on bond rally.  (Inside Investing)

On the “arithmetics of equities.”   (Market Folly)

How much is your Full Tilt Poker claim worth?  (BuzzFeed also Felix Salmon)

A look at the increasingly popular Bayes’ Theorem.  (Farnam Street)


How are we going to manage the demographic decline?  (The Daily Beast)

Is the main cause for the global recession the credit crisis or an innovation crisis?  (Project Syndicate, FT Alphaville)

What does an expanded Panama Canal mean for US ports?  (Quartz)

The story (and economics) of the “greatest hoodie ever made.”  (Slate)


Why Tesla ($TSLA) is like Amazon ($AMZN) and Elon Musk like Jeff Bezos. (Pando Daily)

Why aren’t there more female Fortune 500 CEOs?  (City Journal via Arts & Letters Daily)

How Best Buy ($BBY) can survive, maybe.  (Newsweek)


Why so many people are obsessed with Apple ($AAPL) stock.  (Fortune)

An extended Q&A with Tim Cook CEO of Apple.  (Businessweek)

The real threat Samsung poses to Apple.  (Asymco)


Our smartphones are cutting us off from the world.  (Felix Salmon)

Why did Google kill Google Reader?  (BuzzFeed)

Just how anonymous is your web surfing?  (WSJ)

How quitting Twitter for a month changes your thinking.  (Adam Brault)


An oral history of Freaks and Geeks.  (Vanity Fair via @longreads)

How Mad Men changed television for the better.  (NYTimes)

The 20 best TV shows of 2012.  (Paste Magazine)


Nate Silver talks The Signal and the Noise.  (YouTube via Big Picture)

Barry Ritholtz talks cognitive biases with Michael Covel.  (Trendfollowing)

Investing tips from Hugh Hendry.  (Credit Writedowns)


The sad story of Johnny Evers, Hall of Fame baseball player.  (SI via Longform)

The rise and fall of Lenny Dykstra.  (Newsday via @longform)


A biotech startup is hoping to get the body to create its own drugs.  (Xconomy)

Despite rising gun violence, homicide rates are dropping.  (WSJ)

On the challenge of using computers to diagnose disease.  (NYTimes)


Some ruminations on the 40th anniversary of Apollo 17.  (Scientific American)

Much of Asia is already living with the dangers of global warming.  (Bloomberg)


The case for drinking as much coffee as you like.  (The Atlantic)

Apparently ‘honey laundering‘ is a thing.  (Open via The Browser)

Thanks for checking in with Abnormal Returns. You can follow us on StockTwits and Twitter.

This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment.

The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client.

References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others.

Please see disclosures here.

Please see the Terms & Conditions page for a full disclaimer.